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Statement of Translational Relevance
Quantitation of neuroblastoma-associated mRNA in blood, bone marrow, and peripheral blood stem cells with reverse transcriptase polymerase chain reaction is sensitive and can provide prognostic information for patients with high-risk neuroblastoma prior to relapse. We provide a systematic comparison of disease burden quantification in relapsed patients by standard evaluations versus a new TaqMan® Low Density Array assay for mRNA of five neuroblastoma genes (NB5 assay) and show that the NB5 assay enhances standard evaluations as well as provides independent prognostic information in this population. This biomarker assay has been incorporated into all NANT consortium therapeutic studies in order to validate the assay and prospectively analyze disease burden assessment as well as to provide standard clinical disease response testing in the context of uniform therapy in large numbers of patients.
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Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-16-2647 INTRODUCTION Neuroblastoma (NB) is the most common extracranial solid tumor in children, and 45% of patients have high-risk, metastatic tumors (stage 4) when diagnosed. 1 Although long-term survival has improved over the past 25 years with multi-modal therapy, 50% of patients relapse or have refractory disease. [2] [3] [4] [5] Patients with relapsed NB have a poor prognosis with a five-year overall survival after relapse of 20%. 6, 7 The International Neuroblastoma Risk Group (INRG) reported that time to first relapse, age, stage of disease, and MYCN gene copy number were independently predictive of post-relapse survival. 6 For stage 4 disease, only 8% of those with MYCN non-amplified tumors diagnosed after 18 months of age and 4% of those with MYCN amplified tumors survived five years after relapse. 6 New therapeutic strategies are needed to improve the outcome of patients with refractory or relapsed NB. These likely will be based upon investigations that include next generation sequencing of tumor cells to identify actionable targets, 8 immunological assessments to identify targets for immunotherapy 4 , defining targets in the tumor microenvironment that promote growth and resistance to therapy, [9] [10] [11] and accurately defining disease burden to provide response and prognostic data. 12, 13 Assessment of disease burden by quantifying NB-associated mRNA in blood and bone marrow (BM) with reverse transcriptase polymerase chain reaction (RT-PCR) assays may contribute to response assessment and prognostication. Studies have been performed at diagnosis or during initial therapy prior to disease progression using RT-PCR and have shown that this sensitive method can provide prognostic information for patients with NB. 5, [14] [15] [16] [17] [18] [19] [20] [21] Research. I-meta-iodobenzylguanidine (MIBG) radionuclide scans for bone and soft tissue disease can be subject to inter-observer variation in scoring 23 and are not readily applicable to quantifying changes in known sites of disease or to defining new sites of very minimal disease. Assessment of soft tissue disease response by CT or MRI imaging using RECIST criteria may be affected by intra-tumor variables such as tumor cell differentiation and components of the tumor microenvironment.
The present study determined if quantitative definition of disease in BM and blood with a TaqMan® Low Density Array (TLDA) assay that detected mRNA of the NB-associated genes CHGA (chromogranin A), DCX (doublecortin), DDC (dopadecarboxylase), PHOX2B (pairedlike homeobox 2b), and TH (tyrosine hydroxylase) (NB5 assay) correlated with results from standard clinical evaluations and provided independent information for prognostication.
CHGA, DCX, DDC, PHOX2B, and TH genes are rarely and only weakly expressed by BM or blood mononuclear cells from normal adults but are strongly expressed by neuroblastomas in vivo and by cell lines that are MYCN amplified or non-amplified and by multi-drug sensitive or resistant NB cell lines. The combined signature of all five genes is more sensitive than two genes (TH and PHOX2B) in detecting NB mRNA 5 and is able to detect one NB cell among 10 6 normal cells.
Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-16-2647 Relapsed/refractory neuroblastoma patients were studied since they generally have detectable disease and since evaluations of changes in disease burden could be enhanced by a sensitive and quantitative assay. This is the first prospective study to quantify expression of five NB-associated genes in BM and blood of patients with relapsed/refractory NB and to correlate expression with concurrent CT/MRI and MIBG imaging and morphologic BM evaluations. The NB5 assay improves definition of disease burden and provides prognostic information that is independent from that derived from clinical disease and MYCN gene assessments.
Research. 
PATIENTS AND METHODS
Patients
The study was designed and conducted in accordance with the U.S. Common Rule, the Declaration of Helsinki, and local regulations including the US Code of Federal Regulations Title 21. The study was performed after approval of the protocol and any informed consent documents by an institutional review board at each site. Investigators obtained written consent from all subjects prior to study enrollment.
Patients were treated at a New Approaches to Neuroblastoma Therapy (NANT) Consortium institution and were enrolled in the NANT Biology Study (NANT 2004-05 DOI: 10.1158 /1078 -0432.CCR-16-2647 Sample Processing and NB5 Assay NB5 assays were performed on mononuclear cells from heparinized blood and BM (pooled bilateral aspirates) isolated by density separation with Ficoll-Hypaque. 25 The bilateral aspirates were pooled in order to have a sample more reflective of overall bone marrow disease burden detectable by this assay. The NB5 assay quantified expression of NBassociated genes CHGA, DCX, DDC, PHOX2B, and TH and of housekeeping genes B2M, GAPDH, HPRT1, and SDHA with pre-designed and pre-optimized probe and primer sets (Table A2) 
Statistical Analysis
Where appropriate, standard descriptive and analytic statistical methods such as t-test, ANOVA, ordinary least squares regression, and contingency table analyses were used. patients had only one or two of each assessment type, formally accounting for repeated measures had negligible effect on the results in most analysis or was technically not feasible in selected analyses. Therefore, for consistency we report the analyses that do not account for repeated measures. For the ANOVA analysis of differences in average ΔCT between groups and for regression of ΔCt on clinical evaluations, assays classified as undetectable represented right censored data, and they were analyzed using normal theory maximum likelihood interval regression analysis as implemented in Stata module "intreg".
Because individual patients could have multiple disease evaluations performed during follow-up, and the results of these evaluation could change, implying that the patient is now potentially at higher or lower risk of relapse or progression, time-dependent covariate (TDC)
Cox regression analysis was used to examine the influence of ΔCt and other variables of interest (e.g. CT/MRI, BM morphology) on time to progression 32, 33 . Individual patients could contribute multiple follow-up periods in this analysis, with time 0 reset at study entry or at occurrence of disease progression, and where values of ΔCt, CT/MRI, Curie score, maximum percent bone marrow involvement by morphology were all time varying, i.e. could change at each evaluation during the follow-up period thus shifting individuals to different risk groups at the times of these changes. P-values were based on the likelihood ratio test. Product limit (Kaplan-Meier) curves using these intervals were constructed to visualize the magnitude of the NB5 effect represented in a univariate TDC analysis of NB5. As above, time 0 is reset at study entry or at progression, and patients whose NB5 status changes during follow-up are shifted to the curve representing that new status at the time of the change. Although any one curve may not reflect the outcome of a particular well-defined group of patients with a known NB5
RESULTS
Patients and Disease Status Evaluations
One hundred one patients who submitted at least one specimen for TLDA analysis with relapsed (n=81) or refractory (n=20) NB are included in this study (Table 1) . Three hundred five standard disease evaluations were performed, and concurrent NB5 assay data was obtained for 259 with a median of 3 days between the disease evaluation and NB5 assay (Table 1 
NB5 Assay ΔCt in BM and Blood Specimens
NB mRNA for at least one of the five genes was detected in 185/223 (83%) of BM and 89/142 (63%) of blood specimens using the NB5 assay ( 
obtained a median of 2 days apart (range, 1 to 6 days). Analysis of ΔCt at these 106 time points showed high correlation between BM and blood (Spearman r=0.67, p<0.0001), but also showed that the level of NB mRNA is less in blood than in BM (Figure 1 ). In 19 strongly positive BMs (ΔCT ≤ 8), BM gave a signal that was 7.9 ± 0.46 Ct stronger than blood. BM was negative in only 8% of instances (5/62) when blood was positive, but blood was negative in 35% of instances (31/88) when BM was positive (Figure 1 ).
NB5 Assay ΔCt and Clinical Disease Status
In univariate analysis, BM and blood NB5 ΔCt correlated with both the percentage of NB cells in BM by morphology and with the MIBG Curie score (Figures 2A-2D Table 2 . Note, only evaluations with no missing evaluations of either BM, MIBG and CT/MRI were included in this analysis. Notably, 11/20 (55%) of patients with no clinically detectable disease had NB mRNA detectable in BM and/or blood. Analysis of variance assessed whether tumor burden (non-detectable or detectable disease) contributed independently to the average NB5 ΔCt ( Change in NB5 ΔCt was assessed between pairs of time points where both NB5 ΔCt and clinical disease assessments were performed ( Figure A2 ). Change in NB5 ΔCt in these sequential BM samples was correlated with change in the percentage of BM NB cells (Spearman r=-0.34, p < 0.0001), the MIBG Curie score (r=-0.48, p < 0.0001), and the CT/MRI LD (r=-0.21, p < 0.001). For BM, the change in NB5 ΔCt that was associated with progressive disease (ΔCt for PD specimen minus ΔCt for previous specimen) was -2.7 ± 0.83 and with non-progressive disease was 1.9 ± 0.27 (p < 0.0001, two-sample t-test). For blood, these values were -2.0 ± 0.66 and 0.52 ± 0.25 respectively (p < 0.0001).
NB5 Assay ΔCt and Progression-Free Survival
Time dependent covariate analysis of ΔCt and progression-free survival (PFS) was performed. NB5 assay results were classified as undetectable, ΔCt > 15 and ΔCt ≤ 15, where the cut point of 15 is approximately the median of ΔCt detectable values. All NB5 assays were included in this analysis if they met the criterion of having one subsequent clinical disease assessment. On univariate analysis, both BM and blood NB5 ΔCt were significant predictors of subsequent progression for all patients including those without morphologically detectable NB cells in BM (Figures 3A-3D The NB5 assay using all five genes was compared in this data set with other analyses using other signatures (PHOX2B + TH + DCX; PHOX2B + TH + DDC; PHOX2B + TH; and TH + DCX) based on prior publications 17, 19, 34, 35 (supplemental figure A3) . The correlation between these signatures and the NB5 was very high, but there were a larger number of undetectable results in the signatures with fewer than 5 genes. Dividing the sample in Figure A3 into two groups at various cut points and comparing 1-year PFS, the NB5 signature resulted in a wider separation between groups than the other signatures. ROC analysis confirmed that NB5 signature resulted in a higher AUC than the other signatures for predicting PFS. In addition, individual genes were removed from the NB5 assay and change in AUC was calculated (Table   A4 ). Based on this analysis, no one gene dominates all the others but the singly most influential gene in this context appears to be CHGA whose removal results in 4.8% drop in AUC.
In order to determine whether NB5 ΔCt was associated with disease progression independently of clinically-defined disease and MYCN gene status, multivariate time dependent covariate analysis was performed using time points where all three clinical assessments (CT/MRI, MIBG, and BM morphology) and MYCN data were available and classified as either positive or negative. These analyses confirmed that NB5 ΔCt is significantly associated with PFS independently of clinical disease and MYCN gene status (Table 3) . Analyses using ΔCt as a continuous rather than a categorical variable yielded similar results. 
DISCUSSION
Disease evaluation is important for guiding therapeutic decisions and assessing prognosis. This is the first study of patients with high-risk NB to quantify expression of five NBassociated genes in BM and blood concurrently with standard disease evaluations at several sequential times. We show a high correlation between the quantity of NB-associated mRNA in BM and blood and disease status defined by percent of NB cells in BM biopsy and MIBG Curie score but also show that NB mRNA is detectable when these standard evaluations are negative. Importantly, quantifying NB mRNA in both BM and blood provides an independent predictor of PFS. Thus, the NB5 assay provides a useful new molecular biomarker that improves both assessment of disease and prognostication.
NB mRNA in BM and blood, as quantified by the NB5 assay, were strongly correlated, but the amount in BM was significantly greater. Although it is less invasive to perform this assay on blood samples, our data suggest that BM samples provide more sensitive detection. BM NB5 ΔCt and tumor size suggests that NB cell growth/survival in the two sites may be independent.
In many instances, quantification of NB-associated mRNA in BM and blood using the NB5 assay detected disease when CT/MRI and MIBG scans and morphologic assessment of BM were negative. For example, the NB5 assay detected NB mRNA in BM of 11 of 20 patients and in blood of 4 of 9 patients who were in complete clinical remission. Although not significant by logrank test, 5 of 11 patients with NB5 detectable vs. 1 of 9 with NB5 non-detectable disease in BM subsequently developed progressive disease. Improved sensitivity of disease quantification in BM and blood will likely improve assessment of response to treatment as well as provide an early surrogate for outcome. Although others have reported that quantitative RT-PCR is more sensitive than morphology for detecting BM disease, 14, 16, 36, 37 our study is the first to comprehensively compare quantification of mRNA (for five NB-associated genes) in BM and blood to current standard imaging and bone marrow evaluations. Our data shows that the NB5 assay for mRNA in BM and blood improves assessment of NB disease status.
The most striking result of this study is the association of NB mRNA quantity in BM and blood with PFS of patients with refractory/relapsed NB. This was highly significant for all patients and even for those whose BMs were negative morphologically. In fact, the absence of NB5 detectable mRNA in BM, which is almost always associated with a negative BM morphologically, predicts a high probability of PFS. By contrast, any level of NB mRNA in BM, even when NB cells were not detected morphologically, predicted a poor PFS. Importantly, multivariate analysis demonstrated that the quantity of NB mRNA in BM and blood defined with is the first to demonstrate that subgroups of patients with relapsed/refractory NB can be identified who have different likelihoods of PFS when treated in early phase clinical trials. Our data suggests that quantifying NB mRNA for multiple NB-associated genes in BM and blood will enable risk stratification of patients with relapsed/refractory NB before and during their treatment in early phase clinical trials.
A criticism of an assay using 5 genes would be that there could be increased sensitivity but with addition of false positivity. To answer this, a comparison of the 5-gene signature to other published gene combination signatures was performed ( Figure A3 ). This showed that the NB5 assay is detectible more often and also better able to predict PFS at different cut points. This argues that the positive predictive value is enhanced by quantifying expression of all 5 genes.
Predicting PFS by quantifying NB mRNA with a multi-gene assay could be affected by clinical variables. First, aspirating a single site may not provide BM that is representative of multiple sites with sufficient RNA quality, 36, 38 although one study that utilized immunocytology to identify NB cells indicated that a sensitive assay can overcome this potential problem.
39
To circumvent this problem, we obtained specimens from both iliac crests and pooled them for testing, and the RNA quality for this multi-institution study was excellent. Second, some NB cells may be tightly adherent in the BM microenvironment and not readily aspirated. However, we used biopsy specimens to define NB cells morphologically, and there was only one specimen that had neuropil in the biopsy but that did not have detectable NB mRNA, which suggests that the sensitivity of the NB5 assay renders this an unlikely limitation. Although Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 -0432.CCR-16-2647 testing blood could potentially overcome sampling concerns, there is less NB mRNA in blood than BM, and some blood specimens did not have detectable NB mRNA even though disease was present by standard evaluations. The type of therapy could affect test results, but our finding that NB5 ΔCt predicts PFS for patients enrolled in a variety of early phase clinical trials suggests independence from treatment. However, this needs to be further studied in trials in which patients are uniformly treated and have complete disease assessments along with NB5 assay testing of BM and blood.
Other studies have shown that quantifying mRNA for three and five NB-associated genes (TH, PHOX2B, and DCX; 17 PHOX2B, TH, DDC, GAP43, and CHRNA3 21 ) in BM provides prognostic information for patients with stage 4, high-risk NB at diagnosis and during and at the end of induction therapy. 17, 21 We previously reported that subgroups of high-risk neuroblastoma patients with different outcomes can be identified by quantifying NB mRNA in peripheral blood stem cells obtained during induction therapy with the NB5 assay used in this study.
5
Quantification of mRNA for four NB-associated genes (B4GALNT1, PHOX2B, CCND1, and ISL1) has been reported to predict PFS and overall survival for patients in first or second remission or with refractory disease and treated with the anti-GD2 antibody 3F8. Means and standard errors of NB5 ΔCT were obtained from an analysis that accounts for right censoring due to mRNA levels below the level of detectability of the NB5 assay (see methods). These represent the best estimate of average NB5 ΔCT in the different disease status groups regardless of their detection status. This analysis was performed for patients who had CT/MIBG/BM clinical evaluations and NB5 assay testing. For the categorical analysis, p-values are based on two degree of freedom Cox likelihood ratio test using three NB5 ΔCt categories as shown in Figure 3 , and for the continuous analysis they are based on a two degree of freedom likelihood ratio for linear and quadratic terms for NB5 ΔCt. 
